European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. The Asia Pacific region is expected to register the fastest growth from 2022-2030 due to the presence of the large HPAPI manufacturers in China. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Dosage 95

Dosage Vaccines 95

STAT

MAY 19, 2023

Viral hepatitis affects almost 400 million people and kills more than 1 million each year. Yet it was left off the agenda of the Millennium Development Goals.

Vaccines 236

Vaccines 236

STAT

APRIL 24, 2024

A rise in the number of younger Americans diagnosed with colorectal cancer worries me — early-age onset colorectal cancer is expected to surge by more than 140% by 2030. As a gastroenterologist and cancer researcher, my mission is to help my patients live longer, healthier, and cancer-free lives.

313

313

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030. by 2030 appeared first on European Pharmaceutical Review. The global buccal drug delivery market is projected to grow from $3.38

Dosage 52

Dosage Compounding 52

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Generic Medicine 86

Generic Medicine Chemotherapy 86

PharmaVoice

FEBRUARY 20, 2024

By 2030, the AI market is expected to reach $187.95 A significant growth is predicted for both AI and IoT in healthcare. billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

260

260

pharmaphorum

OCTOBER 26, 2020

CRA’s Life Sciences Practice recently conducted an analysis of the barriers that currently limit reimbursement for many preventive care services and how the evolution of healthcare systems and preventive care offerings could change the demand and uptake of preventive care by 2030. How could payer views change by 2030?

Vaccines 129

Vaccines 129

STAT

OCTOBER 27, 2023

The American College of Emergency Physicians predicted in a 2021 study that there would be a surplus of nearly 8,000 emergency physicians by 2030. While much of the health care workforce is battling staff shortages, the emergency medicine field is trying to figure out how to manage a potential oversupply of physicians. Read the rest…

Hospitals 340

Hospitals 340

European Pharmaceutical Review

OCTOBER 7, 2022

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 billion by 2030 appeared first on European Pharmaceutical Review. A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 86

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 86

European Pharmaceutical Review

AUGUST 17, 2022

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. According to a recent report , the global formulation development outsourcing market size should grow to $61.4

Compounding 76

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Development 76

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Compounding 59

Compounding Labelling 59

Pharma Times

NOVEMBER 30, 2021

Following its recent approval of an injectable HIV-1 treatment from the National institute for Health and Care Excellence (NICE), GlaxoSmithKline (GSK) has high hopes in developing a cure for the virus in the future.

148

148

STAT

DECEMBER 5, 2023

Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030. Plenty of people in pharma and at the banks that invest in it seem to think so. Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 

Drug Pricing 264

Drug Pricing Drug Development 264

STAT

FEBRUARY 29, 2024

It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.)

Drug Development 324

Drug Development 324

pharmaphorum

APRIL 16, 2024

Boehringer Ingelheim says the strongest R&D pipeline in its history is set to deliver 25 new product launches between now and 2030

113

113

Pharmaceutical Technology

JUNE 14, 2023

The recommendations to combat AMR propose that there should be a 20% reduction in the total human consumption of antibiotics by 2030 alongside an even larger pushback against their use in animals, per the 13 June announcement.

Long-Term Care Facilities 52

Long-Term Care Facilities Documentation Hospitals 52

pharmaphorum

DECEMBER 7, 2023

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.

81

81

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

STAT

FEBRUARY 12, 2024

Novo Holdings, the controlling shareholder of Novo Nordisk, plans to invest about $35 billion by 2030 , Reuters writes. Novo Holdings would invest about $5 billion a year in the next five years, and that could go up to $7 billion a year by 2030.

Diabetes 204

Diabetes Vaccines Communication Hospitals 204

Pharmaceutical Commerce

APRIL 17, 2024

A panel uncovers the value in meeting carbon-neutral goals by 2030.

106

106

Outsourcing Pharma

SEPTEMBER 12, 2023

The increasing prevalence of chronic diseases could see the market for active pharmaceutical ingredients (APIs) growing by 7.5% per year, says a report by Prophecy Market Insights.

79

79

The Guardian - Pharmaceutical Industry

OCTOBER 16, 2022

ahin and Özlem Türeci say mRNA Covid vaccine technology could be repurposed to help destroy cancer cells Vaccines that target cancer could be available before the end of the decade, according to the husband and wife team behind one of the most successful Covid vaccines of the pandemic.

Vaccines 101

Vaccines 101

STAT

SEPTEMBER 29, 2022

The Covid-19 pandemic set back many of the global health goals for 2030. One of the most feasible to recover is the target of eliminating human deaths from rabies , thanks to an effective, inexpensive vaccine for dogs.

Vaccines 260

Vaccines 260

STAT

MAY 18, 2023

Most experts predict that Tennessee will be short 5,989 physicians by 2030 , 1,107 of them primary care doctors. By opening a new pathway for doctors trained outside the United States, HB1312 and SB1451 , introduced by state Rep. Sabi Kumar and state Sen. Kerry Roberts, will help Tennessee address its growing physician shortage.

257

257

Pharma Mirror

NOVEMBER 23, 2021

The post AI in Pharma and Biotech Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2030 appeared first on Pharma Mirror Magazine.

Drug Development 52

Drug Development 52

STAT

DECEMBER 27, 2023

And you know why: Demand is intense — so intense that, by 2030, the market for these medicines is forecast to hit $41 billion, according to analysts at TD Cowen. The fundamental issues and intriguing stories that characterized the year gone by will to continue to loom.

Drug Pricing 217

Drug Pricing 217

STAT

FEBRUARY 3, 2023

Certification by the Food and Drug Administration that these products are safe and useful against many common ailments could unleash a $60 billion annual market by 2030. But the FDA turned down industry trade groups , and for good reason.

Compounding 232

Compounding 232

BioPharma Dive

MARCH 1, 2024

Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.

117

117

Pharmaceutical Technology

SEPTEMBER 15, 2023

A new report found that the Remote Patient Monitoring (RPM) sector will grow, since the pandemic revealed the benefits of remote healthcare.

52

52

PharmExec

JANUARY 15, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

STAT

JANUARY 24, 2023

Wegovy is one of a few treatments that are expected to transform weight-loss medicines into a $30 billion market by 2030, according to analysts at Cowen. At issue was a Jan. Continue to STAT+ to read the full story…

Drug Pricing 214

Drug Pricing 214

Drug Channels

APRIL 12, 2022

The econowonks at the Centers for Medicare & Medicaid Services (CMS) recently released the latest projections for U.S. spending on healthcare. See links below.) These data provide our first official look at post-pandemic U.S. healthcare spending. healthcare spending.

92

92

European Pharmaceutical Review

APRIL 3, 2024

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. percent between 2022-2030. Based on the research by Roots Analysis, it is expected to hold 37 percent of the market share by 2030.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Compounding 52

Pharmaceutical Commerce

JANUARY 15, 2024

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

52

52

Drug Channels

JULY 29, 2022

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. healthcare spending.

84

84

STAT

DECEMBER 15, 2022

In a bid to widen access to insulin in primarily low-income nations in Africa, Eli Lilly has agreed to sell active pharmaceutical ingredients and transfer technology to an Egyptian company that expects to supply the life-saving diabetes treatment to as many as 1 million people by 2030.

Diabetes 213

Diabetes Drug Pricing 213

STAT

JANUARY 12, 2023

government to treat as many as 10,000 patients with personalized mRNA cancer immunotherapies by 2030. Other efforts are on the horizon, such as a recent commitment by BioNTech and the U.K. Continue to STAT+ to read the full story…

Vaccines 232

Vaccines 232